Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Orlando Plastic Surgery Center Launches Orlando Weight Loss Program

(EMAILWIRE.COM, January 26, 2012 ) Orlando, FL -- Shockingly, a total of 68.3% of the U.S. adult population over the age of 20 has significant issues with weight! According to the Centers for Disease Control and Prevention, 33.9% of all U.S. adults over the age of 20 are obese, while 34.4% are overweight!

Also, in 2010, usage of fat tissue fillers rose 14% compared to 2009 (American Society of Plastic Surgeons).

Recognizing these startling facts, Orlando Plastic Surgery Center has launched its new Orlando Weight Loss Program.

But, Orlando Plastic Surgery Center does not advocate for individuals to lose as much weight as possible just to look good. Rather, it encourages individuals to lose weight at a healthy pace.

The Orlando Weight Loss Program helps individuals by creating a weight loss plan customized specifically to their unique needs, medically supervises the entire process, and helps individuals look and feel their best from the inside out. And best of all, this is done in a healthy and medically safe way.

“They trust our expertise and opinions, and we take that very seriously as cosmetic and plastic surgery professionals,” said lead surgeon and owner Dr. George Pope.

Orlando Plastic Surgery Center continues to demonstrate its commitment to helping people look and feel their best. It has already helped many patients improve their satisfaction with their lives. Adding a monitored and medically safe weight loss program to its repertoire of services is just one more way it is looking to help the general public.

About Orlando Plastic Surgery Center: Orlando Plastic Surgery Center is regarded as one of Central Florida’s premier plastic surgery centers. Dr. George Pope is one of Central Florida’s most sought-after plastic surgeons (he was voted to the city’s list of best plastic surgeon by readers of Orlando Magazine three years in a row). Services range from Orlando rhinoplasty and nasal contouring, breast augmentation, eyelid surgery / blepharoplasty, revisionist surgery, and Orlando gynecomastia. Liposuction and tummy tuck surgeries are also offered. Dr. Pope and his staff also provide minimally invasive procedures such as laser skin resurfacing, Sculptra Aesthetics, Botox ® injections, Latisse, Juvederm, and Restylane®. Visit orlandoplasticsurgerycenter.com for more information and to read the company’s blog. Orlando Plastic Surgery Center can also be followed on Twitter and “liked” on Facebook.
 

Press Release Courtesy of Online PR Media: http://bit.ly/xqBSD9

Orlando Plastic Surgery Center
Dee Brandt
(407) 857-6261
dbrandt@orlandoplasticsurgerycenter.com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.

WHO calls for safe routes to evacuate east Aleppo sick, wounded
27 Sep 2016 at 6:18am
By Stephanie Nebehay GENEVA (Reuters) - The World Health Organization (WHO) called on Tuesday for dozens of sick and wounded people in the embattled eastern part of the Syrian city of Aleppo to be evacuated through safe corridors for treatment. The Syrian military, helped by Iranian-backed Shi'ite militias and the Russian air force, launched a major campaign to take rebel-held eastern Aleppo last week, where the WHO said only 35 doctors remained to care for at least 250,000 people. "We are talking about only 35 doctors left in east Aleppo to take care of hundreds of wounded people, and the number is increasing," she said.

Why Super Potent Synthetic Opioids Are 'Crazy Dangerous,' DEA Says
27 Sep 2016 at 6:16am
Drugs are significantly more potent than heroin and many other opioids.


Kyrgyz President has recovered, may leave hospital this week: office
27 Sep 2016 at 6:01am

MOSCOW (Reuters) - Kyrgyz President Almazbek Atambayev has recovered significantly and may be discharged from hospital by the end of the week, his office said on Tuesday. Atambayev is being treated for suspected heart problems in Moscow after suffering chest pains on a flight last week. (Reporting by Olzhas Auyezov; Writing by Maria Tsvetkova; Editing by Jack Stubbs)



Halting school meals in Mali could keep thousands of children out of class: U.N
27 Sep 2016 at 5:50am

By Kieran Guilbert DAKAR (Thomson Reuters Foundation) - Taking away school meals from 180,000 pupils going back to class in Mali, where insecurity has closed schools in the north, may deprive even more children of an education, the U.N. World Food Programme (WFP) said on Tuesday. Halting a school meals programme due to a lack of funding will leave these children, in around 1,000 schools across Mali, without a guaranteed healthy meal each day, the WFP said.



Beware the air we breathe
27 Sep 2016 at 5:31am

Health-damaging atmospheric pollutants, which the World Health Organization warned Tuesday affected nine out of every 10 people, originate mainly from industry, heating and transport. Chronic exposure has been linked not only to respiratory ailments, but also cancers, heart disease and stroke.



Bristol-Myers to test Opdivo with Nektar drug for several cancers
27 Sep 2016 at 4:44am

(Reuters) - Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers. The collaboration involves Nektar's NKTR-214, an experimental immuno-stimulatory therapy designed to increase the expression of PD-1 on immune cells. The trials will evaluate the potential for the combination to improve on the current standard-of-care to treat melanoma and cancers of the kidney, colorectal system, bladder and the most common form of lung cancer.


Paris climate targets to cost Asia $300 billion a year, but will help save li...
27 Sep 2016 at 4:42am
By Beh Lih Yi JAKARTA (Thomson Reuters Foundation) - Developing economies in Asia will have to spend $300 billion a year until 2050 to meet targets set by the Paris climate deal, but can expect to save thousands of lives and avoid worsening poverty if they shift to low-carbon growth, research showed on Tuesday. The Asian Development Bank (ADB) said the economic returns of spending on the Paris climate targets far outweighed the costs in the developing region - one of the most vulnerable to climate change and disasters like typhoons and flooding. The Manila-based bank's definition of developing Asia comprises 45 of the ADB's member countries in Asia Pacific including Cambodia, Indonesia, the Philippines and Vietnam.


Amgen's Krypolis fails newly diagnosed multiple myeloma study
27 Sep 2016 at 4:15am

(Reuters) - Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, was not found superior to Takeda Pharmaceutical Co Ltd's Velcade in a late-stage study in previously untreated patients. The U.S. Food and Drug Administration has already approved Kyprolis for patients with relapsed or refractory multiple myeloma who have previously undergone one or more treatments. The latest study tested a regimen of Krypolis against Velcade in patients who also received the chemothereutic agent melphalan and the immunosuppressant prednisone, and were deemed ineligible for stem-cell transplants.



Sanofi gets $43 million U.S. funding to spur Zika vaccine development
27 Sep 2016 at 3:23am

By Reuters Staff Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum. The funding from the HHS' Biomedical Advanced Research and Development Authority (BARDA) will be used for mid-stage trials, expected to begin in the first half of 2018, and for manufacturing, the French drugmaker said. Work on the vaccine began in March as a collaborative effort between the U.S. Department Of Defense's Walter Reed Army Institute of Research (WRAIR), BARDA and the National Institutes of Health.



Thailand investigates four cases of suspected Zika-linked microcephaly
27 Sep 2016 at 1:24am

By Amy Sawitta Lefevre and Pracha Hariraksapitak BANGKOK (Reuters) - Thailand is investigating four suspected cases of Zika-related microcephaly in three babies and a 36-week old unborn baby, the public health minister said on Tuesday, in what could be the first cases of Zika-linked microcephaly in Southeast Asia. Several countries in Southeast Asia have reported increasing cases of infection from the mosquito-borne Zika virus but Thailand has one of the highest numbers in the region, with 349 confirmed since January, including 25 pregnant women.



Child TB deaths set to fall as Kenya launches new drugs
26 Sep 2016 at 11:51pm

By Katy Migiro NAIROBI (Thomson Reuters Foundation) - More children are likely to survive tuberculosis, the leading infectious disease killer, after Kenya introduces child-friendly medicines on Oct. 1 - the first country in the world to do so. Some 155,000 children with TB are set to benefit across 18 countries that have already ordered the new medicines and are preparing to roll them out, starting with Kenya, according to the TB Alliance campaign group that oversaw their development. "Now, with the appropriate treatments, we can make rapid progress in finding and treating children with TB so we can achieve a TB free generation," Kenya's health minister Cleopa Mailu said in a statement on Tuesday.



Over 90% of world breathing bad air: WHO
26 Sep 2016 at 10:23pm

Nine out of 10 people globally are breathing poor quality air, the World Health Organization said Tuesday, calling for dramatic action against pollution that is blamed for more than six million deaths a year. New data in a report from the UN's global health body "is enough to make all of us extremely concerned," Maria Neira, the head of the WHO's department of public health and environment, told reporters. "It is a public health emergency," she said.


Is the Philippines' 'war on drugs' fuelling an HIV epidemic?
26 Sep 2016 at 10:07pm
By David Doyle CEBU, Philippines (Thomson Reuters Foundation) - As Rosita leaves Jose's small office in downtown Cebu in the central Philippines, he passes her a handful of biscuits and six clean needles. Amidst Philippines President Rodrigo Duterte's war on drugs - in which nearly 3,000 people have been killed, according to police - it is safer to be anonymous. Clean needles have been distributed in Cebu City for years, sometimes illegally, in order to prevent the spread of HIV.

Mother sues U.S. hospital for discriminating against dead transgender son
26 Sep 2016 at 3:13pm
The mother of a transgender boy filed a lawsuit against a U.S. hospital on Monday claiming its medical staff repeatedly addressed her son - who later committed suicide - as a girl. In the landmark case, Katharine Prescott argues the Rady Children's Hospital-San Diego (RCHSD) in California discriminated against her transgender son based on his sex. The 14-year-old transgender boy, Kyler Prescott, committed suicide about five weeks after staying at the hospital in 2015 where he was treated for having suicidal thoughts and self-inflicted wounds.

Cancer patients may be overly optimistic about early drug trial participation
26 Sep 2016 at 2:58pm
By Andrew M. Seaman (Reuters Health) - People with cancer may overestimate the possible benefits to them of participating in an early trial of a new medicine, even after talking with a doctor about what to expect, according to a new study from the U.K. So-called phase 1 trials of experimental treatments are intended to test the drug's safety. Just 4 percent to 20 percent of participants may see their cancer respond to the drug, the authors write in the journal Cancer.

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC